KEYMED BIO-B (02162.HK): Proposes RMB Share Issuance and STAR Market Listing on Shanghai Stock Exchange, Subject to Shareholder and Regulatory Approvals

NewTimeSpace News: On 19 August 2026, Keymed Biosciences Inc. (stock code: 02162) published an inside information announcement under Rule 13.09(2) of the Listing Rules and Part XIVA of the Securities and Futures Ordinance, stating that its board resolved on the same day to propose an issuance of ordinary shares to be listed on the STAR Market of the Shanghai Stock Exchange and traded in RMB. The proposed RMB share issuance is subject to and conditional upon, among other things, market conditions, further board approval, approval by the company's shareholders at a general meeting, and obtaining the necessary regulatory approvals.

As of the date of the announcement, apart from the preliminary proposal and the information disclosed therein, the board has no other plans for the proposed issuance and has not made any application to the relevant regulatory authorities. The preliminary proposal approved by the board may change, and any concrete plans and expected timing will only be finalized upon the aforesaid approvals; the proposed issuance may or may not proceed, and there is no guarantee as to whether or when it will be implemented. Shareholders and potential investors are advised to exercise caution when dealing in the company's shares.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.